Carbogen Amcis invests in ADC capacity

- Last updated on GMT

Related tags: Investment

Carbogen Amcis invests in ADC capacity
Carbogen Amcis invests in ADC capacity
Carbogen Amcis AG has become the latest CMO to invest in antibody drug conjugate (ADC) production.

The firm – a unit of India’s Dishman – set out its ADC plan this week, explaining that it has set up a dedicated clean room and clinical supply suite at its plant in Bubendorf, Switzerland and spent almost $1m (Eur 739,000) to upgrade a sterile manufacturing area at its facility in Riom, France.

News of the investment follows just a few weeks after Carbogen Amcis set up a formal collaboration with St Asaph, Wales-based ADC Biotechnology in a deal designed to meld the latter’s solid phase immobilisation production technology with its manufacturing capacity.

Like most of the contract manufacturing organisations (CMO) that have invested in ADC technology recently – Novasep​, Piramal​ and Lonza​ to name three – Carbogen Amcis expects the market for this type of product to grow significantly.

When the ADC Biotechnology deal was signed Carbogen Amcis predicted that: "The commercial value of the ADC drug market is projected to reach $5 billion by 2015" and added that "several ADCs are in late-phase trials, with over 60 in pre-clinical testing."

This optimism was echoed by CEO Mark Griffiths for the latest announcement. He cited drugs like Takeda’s Adcetris​ – which is approved in Europe and the US – Roche’s Kadcyla – cleared in the US and under review in Europe – and Pfizer’s Mylotarg – never approved by the EMA and withdrawn in the US – as key drivers for the investment.

Griffiths said the three drugs “have fueled a growing demand for ADCs and we made the decision to expand our ADC service offer to support customers in the development of next-generation cancer treatments​.”

He added that: “We have taken into account customer feedback and market dynamics and are confident that our enhanced infrastructure will enable us to provide our partners in the pharmaceutical industry a needed resource in drug development.”

Carbogen Amcis did not respond to requests for more information ahead of publication.

Related news

Show more

Related products

show more

Liposomal and Nanoparticle Technology

Liposomal and Nanoparticle Technology

Pfizer CentreOne | 18-Nov-2022 | Technical / White Paper

Medical science is continuously searching for better ways to administer drugs into the body and to maximize the therapeutic effectiveness of the drugs...

GMP manufacturing of buffers and liquid blends

GMP manufacturing of buffers and liquid blends

Actylis – The Partner of Choice | 16-Nov-2022 | Technical / White Paper

Actylis manufactures buffers, process solutions, cleaning solutions, Water for Injection (WFI) for further processing, and custom liquid blends in compliance...

Custom manufacturing of protease inhibitor PMSF

Custom manufacturing of protease inhibitor PMSF

Actylis – The Partner of Choice | 09-Nov-2022 | Technical / White Paper

By combining 75+ years of manufacturing and sourcing expertise, Actylis provides a wide portfolio of GMP ingredients to the pharma & biopharma market,...

Related suppliers

Follow us


View more